At Intelliject, we believe the product is the combination of the “3Ds,” drug, device and data.
From the outset of the development process, we consider what data will be compelling for key decision makers to support the use of the new product, and how clinical studies should be designed in order to generate the appropriate data.
Furthermore, because our designs are influenced by actual users, with the goal of improving on the options that are currently available, we are able to conduct head-to-head studies versus the current standard of care. When conducting studies, we are confident that we will see the benefits designed into the IJ solution, and that this will be reflected in the study results.
Our clinical studies are conducted by world experts in their field and published in top peer-reviewed journals. This ensures that our data, “the 3rd D,” is of the same high quality as the first “2Ds,” the drug and the device.